Formina

Quick links to important sections

Formina

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Formina

Property Description
Active ingredient Sibutramine hydrochloride monohydrate
Form Oral capsule
Pharmacological class Anorexigenic agent (Appetite Suppressant)
Mechanism Group Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Origin Synthetic compound

What Type of Medicine is Formina?

Formina is a synthetic prescription-only medication classified as an anorexigenic agent (antiobesity drug) that is specifically designed to suppress appetite and assist in weight management. Its pharmacological action places it within the group of serotonin-norepinephrine reuptake inhibitors (SNRIs), which defines its central mechanism. This action is clinically recognized and stems from its active compound, Sibutramine, which modulates chemical messengers in the brain. This mechanism of action differentiates it from anti-obesity treatments that only act peripherally, such as those that block the absorption of dietary fat.


Composition and General Purpose

The active therapeutic component in Formina is Sibutramine hydrochloride monohydrate. It is formulated as an oral capsule, which is the standardized dosage form for systemic delivery, allowing the active ingredient to be absorbed into the bloodstream efficiently. The general purpose of this medication is to facilitate a sustained reduction in food consumption by enhancing the body's sensation of satiety. The medicine is intended to help patients feel full, thereby aiding adherence to a reduced-calorie diet, which is typically used as support for adults addressing clinical obesity.

What side effects are possible with Formina?

Possible Side Effects and Safety Information

Common Side Effects

Formina (metformin) is generally well tolerated, but most side effects relate to the gastrointestinal system and are common when starting treatment or increasing the dose. These frequently improve over time. Taking the medication with food can help reduce these effects.

System/Type Common Side Effects (Affecting >1 in 10 People)
Gastrointestinal Diarrhea, nausea, vomiting, abdominal pain, loss of appetite.
Other Metallic taste in the mouth.

Serious but Rare Side Effects

Formina carries a Boxed Warning regarding the risk of a rare, but very serious condition called lactic acidosis, which is a life-threatening medical emergency. The risk is higher in individuals with kidney problems, liver problems, unstable heart failure, excessive alcohol use, or dehydration. Symptoms are non-specific and may include extreme tiredness, severe muscle pain, difficulty breathing, unusual sleepiness, or feeling cold. Seek immediate medical attention if you experience these symptoms.

Long-term use of Formina can also be associated with reduced Vitamin B12 levels, which, if severe, may lead to anemia or nerve issues (neuropathy).

Contraindications and Warnings

Formina is not recommended for use in people with severe kidney disease, metabolic acidosis (including diabetic ketoacidosis), or severe liver impairment. You should inform your healthcare provider if you have heart failure, a history of excessive alcohol consumption, or if you are scheduled for a surgery or an imaging procedure using injectable iodinated contrast dye, as the medication may need to be temporarily stopped.

Overdose and Emergency Response

The official regulatory documents specify that an overdose of Formina (Sibutramine hydrochloride monohydrate) requires immediate medical attention. This action is mandated due to the potential for significant, documented clinical signs, which primarily involve the cardiovascular system. The most frequently reported manifestations in overdose situations are tachycardia (a fast heart rate) and hypertension (high blood pressure). Other documented clinical changes include headache and dizziness.

Management of a suspected overdose is entirely symptomatic and supportive, as no specific antidote is known for Sibutramine. Regulatory information requires that medical personnel institute general measures for overdose management, including securing an adequate airway, ensuring proper oxygenation and ventilation, and maintaining continuous cardiac monitoring. Procedures such as gastric lavage and the use of activated charcoal may be considered. Furthermore, pharmacological intervention, such as the administration of agents like beta-blockers, may be necessary to control severe hypertension and tachycardia. The entire protocol focuses on stabilizing vital signs and monitoring the patient until the effects of the medication subside.

Therapeutic Uses of Formina

What Formina Treats: Main Uses and Benefits

The medication is used for the management of chronic obesity in adult patients who meet specific clinical criteria. This application is indicated for individuals with a Body Mass Index (BMI) of 30 kg/m² or greater, as well as those with a BMI of 27 kg/m² or greater who also manage weight-related conditions such as controlled type 2 diabetes or hypertension.

The core therapeutic domains include addressing dysregulated appetite, supporting the ability to achieve a sustained feeling of fullness (satiety), and facilitating adherence to a reduced-calorie diet. This support contributes to easing the challenges associated with maintaining long-term dietary changes.

Formina helps address issues related to dysregulated appetite by easing impulses toward excessive food consumption. The medication is applied in clinical settings as an adjunct therapy to diet and physical activity. It assists with the pursuit of clinically significant weight loss and may also assist with managing associated metabolic profile markers.

Quick Fact: Support for Appetite Management

The medication is relevant for easing symptoms that interfere with daily functioning by supporting a sense of satiety and improving dietary adherence.

Eligibility and Restrictions for Use

Who Can and Cannot Use Formina?

Formina (Sibutramine) eligibility is determined by strict regulatory rules, primarily focusing on patient safety regarding cardiovascular health and pre-existing conditions. Use is permitted for adult patients with an initial Body Mass Index (BMI) of 30 kg/m^2 or higher, or ge 27 kg/m^2 if combined with risk factors like controlled Type 2 diabetes or hypertension, and only after an insufficient response to diet alone.


Contraindications and Prohibitions

Formina is contraindicated (absolutely prohibited) for use in several populations, as defined by official labeling:

  • Cardiovascular and Cerebrovascular History: Patients with a history of coronary artery disease, congestive heart failure, arrhythmia, stroke, or TIA must not use this medicine. It is also prohibited for those with inadequately controlled hypertension (e.g., blood pressure > 145/90 mmHg).
  • Age and Reproductive Status: The medicine is contraindicated for patients over 65 years of age and during pregnancy and lactation. Women of child-bearing potential are advised to use adequate contraception.
  • Comorbidities: Use is prohibited for patients with a history of major eating disorders (anorexia or bulimia nervosa) or those taking MAOIs or other centrally acting weight loss drugs.

Use Restrictions

Use is not recommended in patients with severe renal impairment or severe hepatic dysfunction. Additionally, the safety and effectiveness of Formina have not been established in children younger than 16 years of age.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Formina's official interaction profile is defined by two mechanisms: metabolic clearance and pharmacodynamic activity, requiring specific regulatory constraints for co-administration.

Contraindicated Combinations and Timing Rules

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the risk of severe serotonergic reactions. A mandatory washout period of at least 14 days is required between stopping an MAOI and beginning Formina, or vice versa. Use with other centrally active appetite suppressants (anorectics) is also strictly prohibited.

Pharmacokinetic and Pharmacodynamic Interactions

Interaction Type Examples Labeled in Regulatory Documents
Serotonergic Reinforcement SSRIs, SNRIs (e.g., Fluoxetine, Venlafaxine), Triptans, certain Opioids (e.g., Meperidine, Fentanyl), Tryptophan, St. John's Wort
CYP3A4 Inhibition Strong inhibitors like Ketoconazole and Erythromycin (increase active metabolite exposure)
Sympathomimetic Effects Decongestants (e.g., Pseudoephedrine, Ephedrine)

These interactions are deemed clinically significant. Co-administration with strong CYP3A4 inhibitors like Ketoconazole is officially documented to increase the exposure (AUC) of the active metabolites by approximately 23%. Conversely, co-administration with CYP3A4 inducers (e.g., Rifampicin) may decrease exposure.

Other Documented Interactions

Administration with a standard meal officially reduces the peak plasma concentration (Cmax) and delays the time to peak (Tmax) of the active metabolites, though total absorption is not significantly changed. Co-administration with alcohol (ethanol) may increase the risk of certain cardiovascular and central nervous system side effects. In populations with moderate hepatic impairment, the active metabolite exposure is officially documented to be increased by 24% compared to healthy individuals.

Mechanism of Action

Formina functions as a non-competitive inhibitor of mitochondrial complex I (NADH:ubiquinone oxidoreductase) within the electron transport chain (ETC). The drug is transported across the cell membrane and localizes in the mitochondrial matrix, where it interacts allosterically with complex I. This molecular interaction decreases the rate of electron transfer from NADH to ubiquinone, thereby reducing complex I activity. The intracellular consequence is a mathbfdecrease in ATP synthesis via oxidative phosphorylation and an alteration in the cellular ATP/AMP ratio.

This shift activates the central energy sensor, mathbfAMP-activated protein kinase (AMPK), through phosphorylation. Activation of the AMPK molecular pathway triggers downstream signaling cascades that modulate multiple cellular processes, including inhibition of gluconeogenesis, stimulation of fatty acid oxidation, and modification of gene expression related to cellular energy balance. At the system level, this leads to a reduction in hepatic glucose output and increased peripheral glucose uptake.

Dosage and Administration Information

The use of Formina (Sibutramine) follows specific, structured instructions defining the standardized method of administration. Formina is administered exclusively via the oral route as a capsule that must be swallowed whole with liquid, irrespective of mealtimes. Administration is required as an adjunctive therapy within a comprehensive weight management program.


Standard Dosing Regimen

The recommended starting regimen is 10 mg taken once daily, typically in the morning. A maximum dose of 15 mg once daily is specified. Dose escalation to the maximum 15 mg is a strictly defined procedure; it may occur if less than 2 kilograms of weight loss is achieved after the initial four weeks of treatment on the 10 mg dose.


Treatment Course and Duration

The total course of administration is generally not recommended to extend beyond 12 months. Furthermore, treatment is discontinued if certain efficacy criteria are not met, such as failing to achieve at least 5% of initial body weight loss within the first three months, or if response remains inadequate after the four-week assessment period on the maximum dose. Specific administration rules exist for certain populations, including that use is not recommended in individuals over 65 years of age or those with severe renal or hepatic dysfunction. If a dose is missed, the standard protocol is to continue with the next scheduled dose and not to take a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Formina

Evidence for Use in Chronic Obesity Management

The research structure for Formina was studied for chronic obesity in Randomized Controlled Trials (RCTs). These short-to-medium term studies, often lasting between six months and a year, were used in research exploring how body weight changes over defined time intervals. The trials typically included adult participants with chronic obesity receiving the medicine as an adjunct to a modified lifestyle regimen.

Systematic reviews that pooled data from these studies describe patterns observed in the treatment groups, generally reporting greater measured reductions in body weight compared to the groups receiving placebo. These research efforts highlight changes measured during the study period and describe patterns where the medicine was observed to be associated with measurements of satiety, an outcome related to dietary change.

Research in Populations with Associated Comorbidities

The medicine was studied for specific subgroups of adults with chronic obesity who also presented with controlled comorbidities, particularly Type 2 Diabetes and Hypertension. These studies examined outcomes related to systemic or functional imbalance by tracking measurements like blood sugar (glucose), HbA1c, and serum lipids.

Findings indicate that the research highlights changes measured in these patient groups, often reporting small shifts in metabolic markers. Studies also monitored outcomes monitoring physiological strain or stress as part of the overall research profile. The evidence contributes to understanding short-term changes, but the studies do not provide context on long-term reduction in major cardiovascular events.

What Remains Uncertain in the Evidence Landscape

Follow-up durations were limited in many of the initial studies, restricting the ability to understand effects over several years. While one large-scale outcomes study was conducted over several years, the long-term data gathered consistently indicates that there is limited information for long-term outcomes regarding a sustained change after the medicine is stopped.

Specifically, the research does not definitively determine the impact on major health issues, meaning there is limited information for long-term outcomes on outcomes related to systemic or functional imbalance. Subgroup findings are uncertain for certain groups, and comparative evidence is lacking against newer therapeutic options.

Frequently Asked Questions (FAQ)

Common questions about Formina (FAQ)


Q: Can Formina cause someone to gain weight?

Regulatory documents indicate that Formina is an antiobesity medication used to facilitate weight loss and its maintenance. However, official studies have noted that weight regain has been observed in clinical research participants after the treatment was stopped.


Q: Why does Formina have a 'Black Box Warning' in the US?

The official Boxed Warning was issued because studies linked the active ingredient, Sibutramine, to an increased risk of serious cardiovascular events. These include non-fatal heart attack, non-fatal stroke, and cardiovascular death, particularly in patients with pre-existing heart conditions.


Q: Is it okay to take another type of pain reliever with Formina?

Formina's official interaction profile notes that it may affect the use of other medicines. Specifically, it can interact with pain relievers that increase serotonin levels (like some opioid pain medicines) or those that affect blood clotting (like NSAIDs). The official documentation emphasizes the importance of understanding the interaction profile when another medicine is added.


Q: Can Formina cause vivid dreams or sleep changes?

Official product information notes that Formina can cause central nervous system effects. Difficulty sleeping, known as insomnia, is reported as a common side effect. Additionally, less common effects such as abnormal or vivid dreams have also been reported.


Q: Does Formina interact with common blood pressure medicines?

Formina is officially associated with measured increases in a patient's blood pressure and pulse rate. Due to this effect, the drug may oppose the action of certain blood pressure-lowering medications. Official documentation describes the necessity of blood pressure and pulse monitoring due to these potential effects.


Q: What are the general expectations for a patient starting Formina?

Official information indicates that Formina is intended to be used as an adjunctive therapy. This term describes using the medication in combination with a comprehensive weight management program, including a reduced-calorie diet and lifestyle changes, for the purpose of achieving and maintaining weight loss.


Q: Can Formina cause dry mouth?

Yes, regulatory documents list dry mouth as one of the very common side effects associated with this medication. This effect occurs frequently in patients taking Formina.


Q: What if I need surgery while taking Formina?

The active compound in Formina may affect platelet function, which are the cells responsible for normal blood clotting. Regulatory information on adverse events notes that this effect could potentially be associated with an increased risk of bleeding during a surgical procedure.


Q: Does Formina affect laboratory test results?

Yes, official reports of adverse events include altered laboratory findings. Specifically, abnormal liver function tests, such as increases in enzymes like AST and ALT, have been reported in patients taking Formina.


Q: Does Formina need to be taken at the exact same time every day?

The medication is prescribed to be taken once daily. The active metabolites created by the body have a relatively long elimination half-life of 14 to 16 hours, which allows for daily dosing.


Q: How quickly can someone expect to feel the effect of Formina?

The time it takes for a medicine's concentration to peak is described in regulatory documents. Pharmacokinetic data show that the maximum plasma concentrations of the active metabolites typically occur within 3 to 4 hours after the dose is taken.


Q: What happens if I stop taking Formina suddenly?

Studies and official information indicate that Formina is intended to help maintain weight loss while in use. After treatment is stopped, clinical studies have observed that weight regain may occur.


Q: Can men and women use Formina for the same purpose?

The medication is indicated for the management of obesity and maintenance of weight loss in adults. Official regulatory documents do not specify a difference in the primary purpose of use based on gender.


Q: Is it possible to become dependent on Formina?

Formina (Sibutramine) is legally classified as a Schedule IV controlled substance. However, clinical studies assessing its potential for abuse concluded that the drug is distinguishable from placebo in abuse potential and lacks the characteristics associated with amphetamine-type abuse liability.


Q: How does Formina affect driving or operating machinery?

Official warnings note that the drug may cause dizziness or somnolence (drowsiness). Official warnings describe that patients should be aware of how the medicine affects them before engaging in activities like driving or operating hazardous machinery.


Q: Is Formina a controlled substance?

Yes, official government agencies classify Formina (Sibutramine) as a Schedule IV controlled substance. This legal classification is due to the drug having a low potential for abuse relative to certain other controlled substances.


Q: How is the safety of Formina monitored after it is released to the public?

The safety of prescription medicines is continually monitored through mandatory post-marketing surveillance. This includes collecting and reviewing adverse event reports and conducting required long-term clinical outcomes studies to assess risk.


Q: Does the evidence show Formina is beneficial for preventing a condition?

Regulatory documents describe the indication of Formina as the management of obesity and the maintenance of weight loss. The medication is not indicated or approved for the prevention of any medical condition.


How should Formina be stored and disposed of?

The storage and disposal of Formina (sibutramine) must adhere strictly to the conditions specified in the official regulatory labeling.

Storage Conditions

Formina must be stored at Controlled Room Temperature (CRT), defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. The capsules must be kept in the original container and kept tightly closed. The product must be protected from light and excessive moisture to maintain stability. As with all medications, it must be stored securely and out of the reach of children.

Disposal Instructions

Formina, a controlled substance, is not on the list of medicines safe to flush. The preferred disposal method is using a community drug take-back program or mail-back envelope. If a take-back program is unavailable, unused medication should be mixed with an unappealing substance (like dirt or used coffee grounds), sealed in a container, and then discarded in the household trash to prevent misuse. All personal information must be scratched out from the label before disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Formina found in:

A-Z Index: